← Eichor
Study identifier: NCT06517888 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

Condition: Vestibular Schwannoma  ·  Sponsor: Akouos, Inc.

PhasePhase 1/Phase 2
Planned participants27
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.

This description comes directly from the study's public registry record.

Talk to the study team

Akouos Clinical Trials  ·  +1 (857) 410-1816  ·  AkouosClinicalTrials@Lilly.com

Always discuss trial participation with your own doctor first.

Locations (4)

Johns Hopkins HospitalBaltimore, Maryland, United StatesRecruiting
Mayo ClinicRochester, Minnesota, United StatesRecruiting
Vanderbilt Bill Wilkerson CenterNashville, Tennessee, United StatesRecruiting
University of Texas SouthwesternDallas, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06517888